Kornimate/medical-research-clean huggingface dataset:
the effect of chlorohexidine gel on tissue healing following surgical exposure of dental implants

Conditions: Implant Infection; Bone Loss

Summary: the aim of this study is to evaluate the healing of peri-implat tissue following surgical uncovering with the adjunctive use of chlorohexidine (chx) gel.

patients who received implants in our department, and scheduled for surgical uncovering of the implants will be asked to participate in this clinical trial (40) patients from department of periodontology, rambam health campus, haifa in israel will be recruited to randomized clinical trial; patients will be divided randomly in to 2 groups: 1. control: following uncovering of the implant a 4 mm height healing abutment will be screwed to the implant (the standard treatment modality) without using chlorohexidine gel or any other gel. 2. test group: following implant exposure this group will receive chlorohexidine 1% gel (corsodyl®) the gel will be applied on the abutment as well as on the implant internal hex and then a 4 mm healing abutment will be connected.

Eligibility criteria:
inclusion criteria: 1. patients who are willing to participate and willing to provide an informed consent. 2. males and females between the ages 18-80 3. in good general health. 4. patients who received dental implants and require implant uncovering (if there is more than 1 implant, a minimum radiographic distance of 3 mm will be required between implants). exclusion criteria: 1. uncontrolled type 1 or type 2 diabetes patients( hba1c\>7). 2. subjects treated for at least 2 weeks with any medication known to affect soft tissue condition within one month prior to baseline examination (e.g., phenytoin, cyclosporine, and chronic use of bisphosphonates). 3. patients who underwent guided bone regeneration during implant placement. 4. patients who used antibiotic during the study or 4 weeks prior to the baseline. 5. active periodontitis patients. 6. subjects with presence of active systemic infectious diseases such as: hepatitis, hiv, history of tuberculosis. 7. pregnant or lactating females.
clinical trial of systolic heart failure treatment of ivabradine hemisulfate sustained-release tablets （first）

Conditions: Chronic Systolic Heart Failure

Summary: ivabradine acts by inhibiting the ionic if current that modulates the pacemaker activity of sinoatrial node cells. the aim of present study is to evaluate the efficacy and safety of ivabradine hemisulfate sustained-release tablets versus placebo in patients with moderate to severe chronic systolic heart failure.


Eligibility criteria:
inclusion criteria: * aged from 18 to 75 years, males or females * willing to provide written informed consent * nyha class ii, iii, or iv for≥4 weeks, in stable clinical condition for ≥4 weeks * optimized and unchanged chronic heart failure medications and dosages for≥4 weeks * sinus rhythm with resting heart rate≥70 b.p.m. * left-ventricular systolic dysfunction, with ejection fraction≥40% documented within previous 1 month exclusion criteria: * unstable cardiovascular condition(for example, hospital admission for worsening heart failure) * recent (\<2 months) myocardial infarction or recent or scheduled coronary revascularization * stroke or transient cerebral ischaemia within previous 4 weeks * severe primary valvular disease * scheduled surgery of valvular heart disease * active myocarditis * congenital heart diseases * peripartum cardiomyopathy * hyperthyroid heart disease * on list for cardiac transplantation * cardiac resynchronization therapy started within previous 6 months * pacemaker with atrial or ventricular pacing (except biventricular pacing)˃40% of the time, or with stimulation threshold at the atrial or ventricular level˃60 b.p.m. * permanent atrial fibrillation or flutter * sick sinus syndrome, sinoatrial block, second and third degree atrio-ventricular block * history of symptomatic or sustained (≥30 s) ventricular arrhythmia unless a cardioverter/defibrillator implanted * cardioverter/defibrillator shock within previous 6 months * family history or congenital long qt syndrome or treated with selected qt-prolonging products(except amiodarone) * contraindication or intolerance to ivabradine or lactulose * severe or uncontrolled hypertension (sbp≥180 mmhg or dbp≥110 mmhg) * known anaemia(hb\<100 g/l) * known moderate or severe liver disease(alt/ast˃3uln), known severe renal disease(cr˃2uln) * pregnant or lactating women and women planning to become pregnant * use of an investigational drug within 30 days of enrollment * has a history of psychological illness/condition that interferes with ability to understand or complete requirements of the study
the effects of dietary fiber in ckd: a systematic review and meta-analysis

Conditions: Chronic Kidney Disease

Summary: chronic kidney disease (ckd) is a debilitating condition in which there is a gradual decline of renal function associated with increased overall mortality. most dietary guidelines for ckd focus on limiting protein intake (nitrogen) and high phosphorus-containing foods. however, increasing dietary fiber has been proposed to increase fecal nitrogen excretion which may ameliorate the progress of ckd. we therefore plan to conduct a systematic review and meta-analysis on clinical trials to assess the effect of fiber on urea and creatinine as classical markers of a state of uremia in individuals with ckd. we hypothesize that increasing fiber intakes will improve urea and creatinine levels in individuals with ckd.


Eligibility criteria:
inclusion criteria: * dietary trials in humans * randomized treatment allocation * suitable control (low fiber) * viable endpoint data exclusion criteria: * non-human studies * nonrandomized treatment allocation * lack of a suitable control (high protein) * no viable endpoint data

Keywords: the effects dietary fiber kidney function ckd patients
a study of hepatitis c virus (hcv) polymerase inhibitor pro-drug in combination with pegasys with or without copegus in patients with chronic hepatitis c (chc) genotype 1 infection.

Conditions: Hepatitis C, Chronic

Summary: this 4 arm study will compare the safety and tolerability of hcv polymerase inhibitor pro-drug in combination with pegasys +/- copegus with the standard of care therapy of pegasys + copegus, in treatment-naive patients with chc, genotype 1. patients will be randomized to receive 1500mg or 3000mg po bid of hcv polymerase inhibitor pro-drug + pegasys, 1500mg of hcv polymerase inhibitor pro-drug + pegasys + copegus or pegasys + copegus for 4 weeks. all patients who receive at least one dose of study medication will receive open label pegasys + copegus for an additional 44 weeks after the 4 week experimental period. the anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, 18-65 years of age; * chc without liver cirrhosis or incomplete/transition to liver cirrhosis, genotype 1; * chronic liver disease consistent with chc. exclusion criteria: * infection with any hcv genotype other than genotype 1; * previous treatment for chc; * medical condition associated with chronic liver disease other than chc; * hiv, hepatitis a, hepatitis b infection.
using the optovue oct to select iol power

Conditions: Fuchs' Endothelial Dystrophy; Cataract

Summary: many patients with endothelial dysfunction also present with cataracts. it is therefore common practice to perform cataract extraction and intraocular lens (iol) implantation during the same operation and immediately prior to descemet's stripping automated endothelial keratoplasty (dsaek), in order to minimize trips to the operating room and the associated risks of ocular surgery. however, the unique posterior corneal anatomy of the dsaek recipient makes it difficult to predict pre-operatively the proper power of iol to place, and some patients end up with a mismatched lens that requires spectacle correction. the current gold standard for iol power calculation (a-scan optical biometry) takes measurements of the anterior surface of the cornea and makes assumptions about the posterior surface that are violated by the unique hourglass shape of the donor dsaek graft. new optical coherence tomography (oct) technology provides us with the ability to measure curvature in both the anterior and posterior aspects of the cornea in order to generate an iol calculation that has the potential to give more accurate results for our dsaek patients. the investigators will be using the optovue to perform corneal power analysis on patients who have already received dsaek and cataract surgery, in order to compare the post-op optovue power calculations to the pre-operative power calculations provided by the a-scan. if the oct is shown to provide accurate iol power calculations, then some patients might be better served by a two-stage procedure where dsaek is performed and then followed six months later by cataract surgery using the oct to calculate iol power.


Eligibility criteria:
inclusion criteria: * 18 year of age or older * diagnosis of fuchs' endothelial dystrophy with cataract * recent history of dsaek with concurrent phacoemulsification \& intraocular lens (iol) implantation exclusion criteria: * diagnosis of ocular comorbidity that might be limiting to visual acuity (glaucoma, retinal disease, surface irregularities, etc.)

Keywords: total corneal power optical coherence tomography descemet stripping endothelial keratoplasty
remifentanil for preventing propofol injection pain in elderly patients

Conditions: Drug Usage

Summary: elderly patients show different pharmacokinetic and pharmacodynamic variables and usually need smaller doses of anesthetic drugs than younger patients. the purpose of this study was to investigate the optimal effect-site concentration of remifentanil for preventing injection pain during propofol induction in elderly patients by the dixon's up-and-down method.


Eligibility criteria:
inclusion criteria: * asa physical status i or ii undergoing general anesthesia exclusion criteria: * neurologic disorder * psychologic disorder * vascular disorder * patients with chronic pain * difficulty in vascular access

Keywords: pain propofol remifentanil
apixaban in patients who undergo cied procedure- randomized pilot study

Conditions: Atrial Fibrillation

Summary: this study is being done to determine if apixaban is more safe, when compared to warfarin, at reducing the risk of bleeding during cied procedures.


Eligibility criteria:
1. signed informed written consent 2. patients are taking warfarin or apixaban chronically 3. patients are at risk of stroke or systemic embolism 4. patients have nvaf 5. patients will undergo cied generator change 6. age 18-90 7. either gender 8. all eligibility criteria must be met exclusion: 1. patient is critically ill, or in unstable condition 2. patient is at high risk for bleeding, has-bled score ≥ 3 3. patient is required to take dual antiplatelet agents in addition to anticoagulant drug. (e.g. recent cardiac stent placement) 4. patients have mechanical cardiac valve or another condition other than nvaf that requires chronic anticoagulation 5. women of childbearing potential with positive pregnant test 6. bilirubin \>2x upper limit of normal, in association with ast/alt/alp \>3x upper limit normal 7. allergy to apixaban and warfarin 8. subjects requiring taking strong dual inhibitors of cyp3a4 and p-gp who already meet the criteria to take 2.5 mg apixaban 9. subjects requiring taking strong dual inducers of cyp3a4 and p-gp (.e.g., rifampin, carbamazepine, phenytoin, st. john's wort) 10. patients who take any investigational drugs within 30 days of enrolling in study. 11. prisoners or subjects who are involuntarily incarcerated. 12. subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.
the physiological effect of high flow oxygen therapy

Conditions: High-flow Nasal Cannula; Non-invasive Positive Pressure Ventilation; Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Summary: although non-invasive positive pressure ventilation (nppv) shows the good curative effect of treating the patients with acute exacerbation of chronic obstructive pulmonary disease (aecopd), some patients do not tolerate nppv or do not benefit from it. high-flow nasal cannula (hfnc) is well tolerated and may be used to patients with aecopd who are intolerant to nppv treatment. this study is to evaluate the physiological effect of hfnc and compare it with nppv.


Eligibility criteria:
inclusion criteria: * aecopd patients with acute hypercapnic respiratory failure exclusion criteria: * other lung/pleural diseases or thoracic deformity * severe heart failure (new york heart association class iv), severe dysrhythmia * unstable angina, or malignant comorbidity * obesity (bmi ≥ 35 kg/m²) * severe obstructive sleep apnea syndrome
mindfulness meditation in bone marrow transplantation

Conditions: Hematologic Malignancy; Bone Marrow Transplantation; Stem Cell Transplantation

Summary: the main purpose of this study is to examine techniques to help patients cope better with the stem cell/bone marrow transplant procedure.

patients will be assigned to one of three study groups: 1. receives the normal standard care; 2. meets with an oncology nurse educator, in addition to the regular nurses on the transplant team. the nurse educator will provide information and answers to patient's questions about the stem cell/bone marrow transplant experience; or 3. is taught mindfulness meditation by a nurse who is trained to be a mindfulness instructor and by an audio cd. mindfulness meditation is a technique that may help in coping with the stress and difficulties associated with cancer and undergoing a stem cell/bone marrow transplant. it involves learning to be in the present moment by paying attention to your breathing, sights, and sounds, and to sensations you may be experiencing, or thoughts and feelings you may be having. mindfulness meditation has been shown to be helpful to patients in the clinic who have cancer and other medical conditions. patients, regardless of random group assignment, will complete a questionnaire 8 different times, from before they are admitted to the hospital until 6 months after discharge. patients will also provide two urine samples while in the hospital to measure the levels of stress hormones present in the urine.

Eligibility criteria:
inclusion criteria: * autologous stem cell transplantation for hematologic malignancy * first transplant * 21 years of age or older * speaks and understands english exclusion criteria: * planned tandem (more than one) transplant * taking corticosteroids on a regular basis for a chronic condition * prior formal mindfulness meditation training * significant cognitive impairment and/or confirmed psychosis or thought disorder

Keywords: meditation mindfulness meditation bone marrow transplant stem cell transplant
ntms for motor mapping of rolandic lesions

Conditions: Glioma; Brain Metastases

Summary: to compare presurgical motor mapping by navigated transcranial magnetic stimulation for surgery (ntms) of rolandic lesions to surgery with mapping without implementing these data into neuronavigation as control. primary objective: permanently new postoperative deficit is lower when the preoperative motor mapping is available to the surgeon

experimental intervention: presurgical motor mapping by navigated transcranial magnetic stimulation and fusion with intraoperative neuronavigation control intervention: presurgical motor mapping by navigated transcranial magnetic stimulation without access of the surgeon to this data follow-up per patient: 6 months duration of intervention per patient: 45 minutes

Eligibility criteria:
key inclusion criteria: * indication for resection of a supratentorial tumor within or adjacent to the primary motor cortex * preoperative ntms mapping of the ipsilateral hemisphere * implementation of the mapping data into preoperative planning * continuous mep monitoring - informed consent key exclusion criteria: * no motor eloquent tumor * infratentorial tumor * no postoperative imaging * prognosis lower than 3 months of survival - age \<18 years

Keywords: glioma brain metastases ntms
a study of anlotinib in subjects with advanced malignancy

Conditions: Advanced Malignancy

Summary: anlotinib is a tyrosine kinase inhibitors (tki) with high effective in inhibiting angiogenesis and tumor cell proliferation by targeting vegfr, pdgfr, fgfr and c-kit. previous phase i trial has shown the potency of anlotinib in treating patients with various cancer types who failed in standard treatment or lack proper treatment regimen. here, a single center, single-arm, phase ii study was conducted to further validate the efficacy and safety of anlotinib in these patients.


Eligibility criteria:
inclusion criteria: * 1) 18\~70 years old; eastern cooperative oncology group (ecog) performance status score of 0 or 1; life expectancy ≥ 3 months. 2) histopathologically confirmed advanced malignancy, including gynecological-related tumors, breast cancer, digestive tract tumors, melanoma, and gastrointestinal stromal tumors. 3) has no effective treatment choice, or failure/recurrence after conventional treatment. 4) if has received chemotherapy, the treatment has been discontinued for at least 30 days. 5) the main organs function are normally. 6) male or female subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study (such as intrauterine devices , contraceptives or condoms) ；no pregnant or breastfeeding women, and a negative pregnancy test are received within 7 days before the randomization. 7) understood and signed an informed consent form. exclusion criteria: * 1）has other malignant tumors. 2) has participated in other anticancer drug clinical trials within 4 weeks. 3) has multiple factors affecting oral medication. 4) has brain metastasis, spinal cord compression, cancerous meningitis. 5) has adverse events caused by previous therapy except alopecia that did not recover to ≤grade 1. 6) has any serious and / or uncontrolled disease. 7) long-term unhealed wounds or fractures. 8) has artery/venous thrombosis prior to the first dose within 6 months. 9) has bleeding tendency or treated with anticoagulants or vitamin k antagonists. 10) has drug abuse history that unable to abstain from or mental disorders. 11)has history of immunodeficiency, including hiv positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation. 12) according to the judgement of the researchers, there are other factors that subjects are not suitable for the study.
the effect of transcranial direct current stimulation for chronic pain on ophthalmologic parameters

Conditions: Chronic Pain

Summary: tdcs is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to modulate the level of cortical excitability.several studies have demonstrated that tdcs applied over the sensory-motor cortex has been able to decrease pain sensation and to increase pain threshold in healthy subjects and in chronic pain patients. the aim of this study was to test whether daily sessions of anodal tdcs repeated for 5 consecutive days may be effective in reducing pain in a large number of chronic pain patients. the cathode is usually applied over the right forhead above the eye. the aim of the study is to test whether daily sessions of tdcs repeated for 5 consecutive days will influence on ophthalmologic parametrs.

tdcs is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to modulate the level of cortical excitability.several studies have demonstrated that tdcs applied over the sensory-motor cortex has been able to decrease pain sensation and to increase pain threshold in healthy subjects and in chronic pain patients. the aim of this study was to test whether daily sessions of anodal tdcs repeated for 5 consecutive days may be effective in reducing pain in a large number of chronic pain patients. the cathode is usually applied over the right forhead above the eye. the aim of the study is to test whether daily sessions of tdcs repeated for 5 consecutive days will influence on ophthalmologic parametrs. patients will recieve tdcs in a 5-day period of treatment. the participants will go through full ophtalmologic examination before and after the treatmnet in addition to the ophtalmologic examination pain will be measured using visual analog scale (vas) for pain and the short form mcgill questionnaire (sf-mpq). disability will be measured using the ( pain disability index (pdi) of life-54 scale (msqol-54). depressive symptoms and anxiety will also be evaluated using the center for epidemiological studies-depression scale and the state-trait anxiety inventory (stai). cognitive function will be mesured using minimental test.

Eligibility criteria:
inclusion criteria: * patients who suffer from chronic pain vas\>4 exclusion criteria: * pregnancy * scalp lacerations * history of seizures * metal implants in the head * heart pace maker * ophthalmologic disease. * the presence of deep brain stimulation system
efficacy and safety of topically applied medical therapy for the treatment of pediatric glaucoma

Conditions: Childhood Glaucoma

Summary: objectives: the study will assess the ocular hypotensive effect of latanoprost and dorzolamide in a selected sample of patients affected by primary pediatric glaucoma (pg), refractory to surgical procedures. safety will be assessed, too.in the first version of the protocol 96 eyes were forecasted to complete the enrolment. the protocol was then amended and now to complete the study 68 eyes should be included. this number of eyes could be achieved by recruiting from 34 to 68 patients due to not in all patients both eyes should be eligible for the study.

study design: single arm, prospective, experimental study. due to ethical reasons and in order to adhere as much as possible to current clinical practice, the presence of a control arm is not planned. due to the non-comparative nature of the study, no blinding of treatment is planned.

Eligibility criteria:
inclusion criteria: * children of either sexes, aged 0-12 years * diagnosis of mono- or bilateral primary congenital glaucoma * iop greater than or equal to 22 mmhg and lower than 27 mmhg * only one previous ocular hypotensive surgical procedure for treatment of glaucoma among the following: goniotomy, trabeculotomy, trabeculotomy with adjunct of mitomycin c) (only for medical treatment at least one month before) * parent informed consent to data processing (at registration) * parent informed consent before any study procedure exclusion criteria: * secondary glaucoma (sturge-weber syndrome, type i neurofibromatosis, retinoblastoma, steroid-induced glaucoma, etc.) * presence of concomitant abnormalities of the anterior segment of the eye (cataract, iridocorneal dysgenesia, congenital uveal ectropion uvea, etc.) * previous treatment with the study drugs * presence of concomitant systemic diseases (asthma, hypertension, cardiac disease, renal failure, etc.) that needs treatment with drugs, that could influence iop (steroids, beta-blockers, angiotensin-converting-enzyme inhibitor -inhibitors diuretics, etc.) * abnormalities of the cornea that could influence iop readings (marked cornea edema)

Keywords: intraocular pressure latanoprost dorzolamide